Загрузка...
Early Biosimilars Face Hurdles to Acceptance: The FDA Has Approved Few, So Lack of Competition Is Keeping Prices High
Biosimilars are a highly anticipated arrival in the pharmacy. However, the undermanned and underfunded FDA struggles to guide, regulate, and approve them.
Сохранить в:
| Опубликовано в: : | P T |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MediMedia USA, Inc.
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4894512/ https://ncbi.nlm.nih.gov/pubmed/27313433 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|